Hodgkin lymphoma – The German HD21 trial compared BrECADD (brentuximab, etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone) chemotherapy with the current standard BEACOPP for patients with advanced stage Hodgkin lymphoma. The 4-year progression-free survival was significantly better for patients receiving BrECADD, and it also decreased treatment duration to 3-months and had a favourable tolerability. BrECADD sets a new benchmark for adult patients with advanced Hodgkin lymphoma.
Hodgkin lymphoma – The German HD21 trial
